Hepatitis B

Hepatitis B is a serious disease caused by a virus that attacks the liver. The virus, which is called hepatitis B virus (HBV), can cause lifelong infection, cirrhosis (scarring) of the liver, liver cancer, liver failure, and death. Transmission occurs when blood or body fluids from an infected person enter the body of a person who is not immune.

Vaccination: is given as three injections. (0, 1, 6 month)

Protection: is about 10 years after full vaccination.

Side effects:

• Cold or flu-like symptoms

hepb Resource:

RSV fusion (F) protein DNA vaccine provides partial protection against viral infection.
Wu H, Dennis VA, Pillai SR, Singh SR.
Virus Res. 2009 Oct;145(1):39-47. Epub 2009 Jun 21
[Infectiology and tropical medicine 2009].
Löscher T, Bogner JR.
Dtsch Med Wochenschr. 2009 Jun;134(25-26):1343-8. Epub 2009 Jun 10. German. No abstract available.
Intranasal vaccination of young Holstein calves with Mannheimia haemolytica chimeric protein PlpE-LKT (SAC89) and cholera toxin.
Confer AW, Ayalew S, Step DL, Trojan B, Montelongo M.
Vet Immunol Immunopathol. 2009 Dec 15;132(2-4):232-6. Epub 2009 May 4. No abstract available.
Modeling spatial heterogeneity of disease risk and evaluation of the impact of vaccination.
Ali M, Emch M, Yunus M, Clemens J.
Vaccine. 2009 Jun 8;27(28):3724-9. Epub 2009 Apr 17
The mast cell activator compound 48/80 is safe and effective when used as an adjuvant for intradermal immunization with Bacillus anthracis protective antigen.
McGowen AL, Hale LP, Shelburne CP, Abraham SN, Staats HF.
Vaccine. 2009 Jun 2;27(27):3544-52. Epub 2009 Apr 14
CCR7-CCL19/CCL21-regulated dendritic cells are responsible for effectiveness of sublingual vaccination.
Song JH, Kim JI, Kwon HJ, Shim DH, Parajuli N, Cuburu N, Czerkinsky C, Kweon MN.
J Immunol. 2009 Jun 1;182(11):6851-60
Intranasal immunization with recombinant toxin-coregulated pilus and cholera toxin B subunit protects rabbits against Vibrio cholerae O1 challenge.
Kundu J, Mazumder R, Srivastava R, Srivastava BS.
FEMS Immunol Med Microbiol. 2009 Jul;56(2):179-84. Epub 2009 May 5
Effectiveness and economic analysis of the whole cell/recombinant B subunit (WC/rbs) inactivated oral cholera vaccine in the prevention of traveller's diarrhoea.
López-Gigosos R, Garcia-Fortea P, Calvo MJ, Reina E, Diez-Diaz R, Plaza E.
BMC Infect Dis. 2009 May 16;9:65
Public health. The cholera crisis in Africa.
Bhattacharya S, Black R, Bourgeois L, Clemens J, Cravioto A, Deen JL, Dougan G, Glass R, Grais RF, Greco M, Gust I, Holmgren J, Kariuki S, Lambert PH, Liu MA, Longini I, Nair GB, Norrby R, Nossal GJ, Ogra P, Sansonetti P, von Seidlein L, Songane F, Svennerholm AM, Steele D, Walker R.
Science. 2009 May 15;324(5929):885. No abstract available.
Intramuscular delivery of a cholera DNA vaccine primes both systemic and mucosal protective antibody responses against cholera.
Xu G, Wang S, Zhuang L, Hackett A, Gu L, Zhang L, Zhang C, Wang H, Huang Z, Lu S.
Vaccine. 2009 Jun 12;27(29):3821-30. Epub 2009 Apr 23
Cost-benefit comparisons of investments in improved water supply and cholera vaccination programs.
Jeuland M, Whittington D.
Vaccine. 2009 May 18;27(23):3109-20. Epub 2009 Mar 10
M-cell targeting of whole killed bacteria induces protective immunity against gastrointestinal pathogens.
Chionh YT, Wee JL, Every AL, Ng GZ, Sutton P.
Infect Immun. 2009 Jul;77(7):2962-70. Epub 2009 Apr 20
Reduction of travellers' diarrhoea by WC/rBS oral cholera vaccine in young, high-risk travellers.
Torrell JM, Aumatell CM, Ramos SM, Mestre LG, Salas CM.
Vaccine. 2009 Jun 19;27(30):4074-7. Epub 2009 May 3
Oral cholera vaccine use in Zanzibar: socioeconomic and behavioural features affecting demand and acceptance.
Schaetti C, Hutubessy R, Ali SM, Pach A, Weiss MG, Chaignat CL, Khatib AM.
BMC Public Health. 2009 Apr 7;9:99
Interleukin-17 is a critical mediator of vaccine-induced reduction of Helicobacter infection in the mouse model.
Velin D, Favre L, Bernasconi E, Bachmann D, Pythoud C, Saiji E, Bouzourene H, Michetti P.
Gastroenterology. 2009 Jun;136(7):2237-2246.e1. Epub 2009 Mar 9
Protection against Pneumococcal colonization and fatal pneumonia by a trivalent conjugate of a fusion protein with the cell wall polysaccharide.
Lu YJ, Forte S, Thompson CM, Anderson PW, Malley R.
Infect Immun. 2009 May;77(5):2076-83. Epub 2009 Mar 2
Kinetics of immune responses to influenza virus-like particles and dose-dependence of protection with a single vaccination.
Quan FS, Yoo DG, Song JM, Clements JD, Compans RW, Kang SM.
J Virol. 2009 May;83(9):4489-97. Epub 2009 Feb 11
Cost-benefit of WC/rBS oral cholera vaccine for vaccination against ETEC-caused travelers' diarrhea.
Lundkvist J, Steffen R, Jönsson B.
J Travel Med. 2009 Jan-Feb;16(1):28-34. Erratum in: J Travel Med. 2009 Mar-Apr;16(2):147.
Mucosal immunization with polyamine transport protein D (PotD) protects mice against nasopharyngeal colonization with Streptococcus pneumoniae.
Shah P, Briles DE, King J, Hale Y, Swiatlo E.
Exp Biol Med (Maywood). 2009 Apr;234(4):403-9. Epub 2009 Jan 28
Mucosal vaccination approach against mosquito-borne Japanese encephalitis virus.
Harakuni T, Kohama H, Tadano M, Uechi G, Tsuji N, Matsumoto Y, Miyata T, Tsuboi T, Oku H, Arakawa T.
Jpn J Infect Dis. 2009 Jan;62(1):37-45
First Prev 4 5 6 7 8 9 10 11 12 Next Last 67/1332 Jump: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67

To top Back to list of vaccination • Home

---

Show map | Diseases | Vaccination | Chronic disease | Medicine | Pregnancy | Heat & Sunburn | Cold | Security | Useful tips | Faq | News

TraveldoctorOnline 2001 • Disclaimer • webmaster